Peer-Reviewed Original Research Articles |
| 1. | Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal Adenocarcinoma of the Prostate - Clinical Features and Implications after Local Therapy. Cancer 115(13):2872-80, 7/2009. e-Pub 4/2009. PMID: 19402048. |
| 2. | Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. e-Pub 5/4/2009. PMID: 19414670. |
| 3. | Williams BJ, Fox BD, Sciubba DM, Suki D, Tu SM, Kuban D, Gokaslan ZL, Rhines LD, Rao G. Surgical management of prostate cancer metastatic to the spine. J Neurosurg Spine 10(5):414-22, 5/2009. PMID: 19442002. |
| 4. | Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 115(6):1310-7, 3/15/2009. PMID: 19156903. |
| 5. | Bilen MA, Waguespack SG, Tannir NM, Pravinkumar SE, Tamboli P, Tu SM. Multisystem crisis in a patient with presumptive renal cell carcinoma. Clin Genitourin Cancer 6(2):128-30, 9/2008. PMID: 18824438. |
| 6. | Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res 14(12):3729-36, 6/15/2008. PMCID: PMC2562877. |
| 7. | Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39). e-Pub 5/19/2008. PMCID: PMC2562662. |
| 8. | Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98(8). e-Pub 3/25/2008. PMID: 18362942. |
| 9. | Tu SM, Lin SH. Current trials using bone-targeting agents in prostate cancer. Cancer J 14(1):199, Jan-Feb, 2008. PMID: 18303481. |
| 10. | Spiess PE, Tannir NM, Brown GA, Liu P, Tu SM, Evans JG, Pisters LL. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology 70(6):1173-8, 12/2007. PMID: 18158041. |
| 11. | Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer 110(12):2700-8, 12/2007. PMID: 17948916. |
| 12. | Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13(19):5816-24, 10/2007. PMID: 17908974. |
| 13. | Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW.. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89(8):1794-801, 8/2007. PMID: 17671020. |
| 14. | Cheng CJ, YeXC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC.. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5(7):675-84, 7/2007. PMCID: PMC2000833. |
| 15. | Ye XC, Choueiri M, Tu SM, Lin SH. Biology and clinical management of prostate cancer bone metastasis. Front Biosci 12:3273-86, 5/2007. PMID: 17485298. |
| 16. | Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitxhusen K, Millikan RE, Pisters LL.. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 109(2):198-204, 1/2007. PMID: 17171704. |
| 17. | Spiess PR, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pister LL.. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol 177(1):131-8, 1/2007. PMID: 17162023. |
| 18. | Tuziak T, Spiess PE, Abrahams NA, Wrona A, Tu SM, Czerniak B. Multilocular cystadenoma and cystadenaocarcinoma of the prostate. Urol Oncol 25:19-25, 2007. |
| 19. | Choueiri MB, Tu SM, YU-Lee LY, Lin SH. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev 25(4):601-9, 12/2006. PMID: 17160554. |
| 20. | Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107(7):1483-90, 10/2006. PMID: 16944541. |
| 21. | Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 8/2006. PMID: 16795067. |
| 22. | Pagliaro LC, Perez CA, Tu SM, Daliani DD. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma. Urol Oncol 24(6):487-91, Nov-Dec, 2006. PMID: 17138128. |
| 23. | Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 23(31):7904-10, 11/2005. PMID: 16258090. |
| 24. | Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108-21, 6/2004. PMID: 15169797. |
| 25. | Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203(2):688-95, 6/2004. PMID: 15141384. |
| 26. | Tu SM, Lin SH. Clinical aspects of bone metastases in prostate cancer. Cancer Treat Res 118:23-46, 2004. PMID: 15043187. |
| 27. | Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol 21(5):342-8, Sep-Oct, 9/2003. PMID: 14670540. |
| 28. | Tu SM, Lin SH, Logothetis C. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 95(15):1174-5; author reply 1175, 8/2003. PMID: 12902452. |
| 29. | Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 97(12):2988-94, 6/2003. PMID: 12784333. |
| 30. | Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 20(13):2965-70, 7/2002. PMID: 12089226. |
| 31. | Christos Papandreou, Danai D Daliani, Peter FThall, Shi-Ming Tu, Xuemei Wang, Adriana Reyes, Patricia Troncoso, Christopher J Logothetis. Results of a Phase II Study with Doxorubicin, Etoposide, and Cisplatin in Patients with Fully Characterized Small-Cell Carcinoma of the Prostate. J Clin Oncol 20(14):3072-3080, 7/2002. PMID: 12118020. |
| 32. | Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94(10):2610-7, 5/2002. PMID: 12173328. |
| 33. | Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Jr, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20(5):1361-7, 3/2002. PMID: 11870180. |
| 34. | Sexton WJ, Lance RE, Reyes AO, Pisters PW, Tu SM, Pisters LL. Adult prostate sarcoma: the M.D. Anderson Cancer Center Experience. J Urol 166(2):521-5, 2001. PMID: 11458058. |
| 35. | Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate a randomised phase II trial. Lancet 357(9253):336-41, 2001. PMID: 11210994. |
| 36. | Park DS, Vassilopoulou Sellin R, Tu SM. Estramustine-related hypocalcemia in patients with prostate carcinoma and osteoblastic metastases. Urology 58(1):105, 2001. PMID: 11445494. |
